A poison pill works by letting a company’s board issue a flood of deeply discounted shares the moment a hostile bidder crosses a set ownership threshold, diluting the bidder’s stake so badly that the takeover becomes too expensive to finish. The formal name is a shareholder rights plan. It doesn’t legally block an acquisition; it forces the would-be acquirer to negotiate with the board instead of buying up shares on the open market or going directly to shareholders with a tender offer. The same feature that protects shareholders from lowball bids can also insulate an underperforming board, which is why the tool remains controversial.
The Trigger and the Dilution
A board adopts a rights plan by issuing one right for every outstanding share of common stock, distributed to existing shareholders as a kind of dividend. The rights sit dormant and trade invisibly alongside the common stock. Nothing happens until a hostile bidder acquires beneficial ownership above the trigger, which most plans peg between 10% and 20% of outstanding shares.1Harvard Law School Forum on Corporate Governance. Triggering a Poison Pill
The instant the bidder crosses that line, the rights detach from the common stock and become separately exercisable by every shareholder except the bidder. Each right lets the holder buy additional shares at a steep discount, typically paying an exercise price that gets them stock worth roughly twice what they paid. A plan with a $200 exercise price, for example, would entitle each right-holder to receive $400 worth of shares. The net effect is the same as buying stock at half price.
This wave of new shares massively dilutes the bidder’s stake. If someone spent billions accumulating 20% of a company, a triggered pill could slash that holding to single digits overnight without them selling a single share. The cost of reaching a controlling interest balloons so dramatically that most bidders abandon the hostile approach. That’s the point. The pill is a threat designed never to be used, and it works by making the alternative to negotiation financially ruinous.
Flip-In and Flip-Over Structures
Most modern pills use a flip-in structure. When the bidder crosses the trigger, non-bidder shareholders buy discounted stock in the target company itself. Dilution happens immediately, inside the company the bidder is trying to acquire. Boards overwhelmingly adopt this version because it delivers consequences the moment the threshold is breached.
The less common flip-over structure activates only after the hostile bidder has already acquired the target and attempts a back-end merger to absorb it. At that point, the target’s original shareholders gain the right to buy the acquiring company’s stock at a deep discount, threatening to dilute the acquirer’s own equity and making the merger destructive to the bidder’s shareholders. It’s a booby trap wired to the second step of a two-step takeover.
Nearly every plan you’ll encounter is a flip-in pill. Many include a flip-over feature as a backstop, but the flip-in does the heavy lifting because it deters accumulation before the bidder gains control.
Redemption: Why the Pill Is a Negotiating Tool
Every well-drafted rights plan includes a redemption clause that lets the board cancel the pill before it triggers. The board votes to redeem all outstanding rights for a nominal price, often a penny or a few cents per right. This ability to defuse the plan is what turns the pill into a negotiating tool rather than a doomsday device. A board might redeem the pill because the bidder raised its offer to a price the board considers fair, or because a white-knight bidder emerged with a better deal.
Timing is the critical detail. In most plans, the board’s power to redeem expires once the trigger threshold is crossed. Some plans include a short grace period after the trigger, giving the board a final window to negotiate. Once the rights have been exercised and discounted shares issued, there’s no reversing it. That’s why hostile bidders announce their intentions before crossing the threshold. They want the board to redeem the pill and negotiate, not force the dilution event.
How Shareholders Push Back
Because the board controls the pill, the primary shareholder countermove is to replace the board. Delaware courts have recognized that a proxy contest to elect directors willing to redeem the pill is the safety valve that keeps the mechanism legal. A pill that made proxy contests realistically unattainable would be struck down as preclusive. The pill is legal partly because shareholders retain the power to fire the directors who put it in place.
Shareholders cannot force redemption directly. Delaware courts have held that a shareholder-adopted bylaw requiring the board to redeem a pill would conflict with the board’s statutory authority to manage the corporation. The path runs through elections: wage a proxy fight, replace enough directors, and the new board can vote to redeem or negotiate.
A pill backed by a board with strong shareholder support is far more durable than one maintained by directors investors want to replace. An activist or hostile bidder who can credibly threaten to win a proxy fight often doesn’t need to actually run one. The board, reading the situation, may negotiate or redeem on its own.
The Legal Limits on What a Board Can Do
Poison pills exist because courts have said boards can adopt them. The landmark case came in 1985, when the Delaware Court of Chancery upheld Household International’s rights plan as a valid exercise of business judgment even though no hostile bid was pending at the time. The court found the plan served a rational corporate purpose and that the board’s authority to issue stock rights extended to pre-planned defensive measures, not just reactive ones.2Justia. Moran v Household Intern Inc A board can put a pill in place proactively, without waiting for a specific threat.
Most large U.S. corporations are incorporated in Delaware, which makes Delaware case law the dominant framework for pill disputes. Under the enhanced scrutiny standard from the same year’s Unocal decision, a board deploying defensive measures must show two things: reasonable grounds to believe a threat existed, and a response proportionate to that threat.3Justia. Unocal Corp v Mesa Petroleum Co The defense has to match the danger.
Proportionality has real teeth. In 2021, the Delaware Court of Chancery struck down a pill adopted by The Williams Companies that combined a 5% trigger, an unusually broad “acting in concert” provision that could aggregate unrelated shareholders’ holdings, and a daisy-chain clause linking parties with no direct agreement. The court found the collection of aggressive features bore no reasonable relationship to the stated corporate objective and declared the pill unenforceable.
A pill is also not permanent. Under what’s known as the Revlon duty, once a board decides to sell the company, its role shifts from defender to auctioneer. Directors in a change-of-control transaction must work to maximize the sale price rather than block all comers. A board that clings to a pill after deciding to sell, or that uses it to favor a preferred bidder for reasons unrelated to price, breaches its fiduciary duty.
Dead-Hand and Slow-Hand Pills
Some boards have tried to make pills proxy-proof. A dead-hand pill restricts redemption power to the directors who originally adopted the plan or their approved successors, so a new slate of directors elected through a proxy fight would inherit a pill they can’t remove. A slow-hand variant imposes a waiting period, such as six months, before newly elected directors can redeem.
Delaware courts have rejected both. In the late 1990s, the Court of Chancery struck down a dead-hand pill as improper interference with a future board’s authority, and likewise found a slow-hand variant disproportionate to any threat. These variants are effectively dead letter in Delaware.
NOL Preservation Pills: A Different Purpose
Not every pill targets a hostile bidder. Companies with large net operating loss carryforwards sometimes adopt a rights plan specifically to protect those tax assets. Under Section 382 of the Internal Revenue Code, a company’s ability to use accumulated losses to offset future taxable income is sharply limited if one or more 5-percent shareholders increase their collective ownership by more than 50 percentage points within a three-year window.4Office of the Law Revision Counsel. 26 USC 382 – Limitation on Net Operating Loss Carryforwards and Certain Built-In Losses Following Ownership Change An ownership change under this rule can destroy hundreds of millions of dollars in tax benefits.
To prevent that, NOL pills set their trigger at 4.99%, just below the 5% level Section 382 monitors. Existing shareholders already holding 5% or more are typically grandfathered in and allowed only minimal additional purchases. The Delaware Court of Chancery upheld this type of low-trigger pill in a 2010 case involving Selectica, Inc., finding the board reasonably believed the NOL assets had value worth protecting and that the low threshold was justified by the specific tax threat.
NOL pills draw extra scrutiny because the 4.99% trigger sits far below the usual range and can restrict ordinary trading. Courts and investors evaluate them by asking whether the NOL assets genuinely have significant value and whether the terms are tailored to the tax threat.
How Pills Play Out in Practice
Pills are adopted frequently but triggered almost never. The whole point is deterrence. A well-publicized example came in April 2022, when Twitter’s board adopted a rights plan with a 15% trigger after Elon Musk disclosed a large stake and made an unsolicited acquisition offer. The plan was set to expire within one year and allowed the board to continue evaluating proposals in the company’s best interests. Twitter ultimately negotiated a deal with Musk rather than relying on the pill indefinitely.
The COVID-19 pandemic produced an unusual surge in pill adoptions. As stock prices cratered in early 2020, companies that had been trading at comfortable valuations suddenly became vulnerable to opportunistic acquisitions. At least 45 firms adopted pills between March and April of that year, a sharp spike considering that only about 25 S&P 500 companies had an active pill at the end of 2019.5Harvard Law School Forum on Corporate Governance. The Return of Poison Pills: A First Look at Crisis Pills Most of these crisis pills were short-term plans with one-year expirations, adopted defensively even where no specific bidder had emerged.
Institutional investors and proxy advisory firms have pushed back against long-term pills adopted without a shareholder vote. The prevailing expectation is that a pill lasting more than one year should go to shareholders for approval, and that any renewal or material modification of an existing pill requires a vote. Boards that ignore this expectation risk “against” recommendations on their own re-election, which can be a more potent threat to entrenched directors than the hostile bidder ever was.